Pharmaceuticals, Biotechnology and Life Sciences
PARP7 is a Novel Tumor Dependency, Enabling Cancer Cells to Evade the Immune System First Ever Clinical Evaluation of a…
CLEVELAND & NEW YORK–(BUSINESS WIRE)–BioMotiv, a mission-driven drug development accelerator that advances breakthrough discoveries from research institutions into therapeutics, and…
European Approval Based on KEYNOTE-426 Trial Results Demonstrating Significant Improvement in Overall Survival with KEYTRUDA in Combination with Axitinib Compared…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced the appointments of experienced…
DUBLIN–(BUSINESS WIRE)–The “North America Pharmaceutical & Cosmetics Industrial Robots Market 2014-2025 by End-user, Application, Product Type and Country” report has…
– Advancing clinical development of SYNB1618 as a novel therapy to potentially serve all patients with phenylketonuria – – Synlogic…
– Advancing clinical development of SYNB1618 as a novel therapy to potentially serve all patients with phenylketonuria – – Synlogic…
— Bill & Melinda Gates Foundation invests $55 million in an infectious disease collaboration that could reach up to $100…
— Advancing pipeline of synthetic-lethal, precision oncology therapies for multiple solid tumor indications — — Financing supports initiation of two…
– Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder…